Parkinson's disease (PD) remains a major challenge in neurodegenerative drug development, particularly for disease-modifying therapies and regenerative approaches such as stem cell transplantation. In 2025, an expert panel from the Chinese Research Hospital Association released updated guidance on selecting preclinical PD models for drug and cell therapy evaluation.
This article summarizes key insights from the guideline, covering the distinctions among classical neurotoxin models, the strengths of genetic models, and the translational value of nonhuman primates (NHPs). As a CRO specializing in NHP Pharmacology, Prisys Biotech provides validated PD models and quantitative evaluation platforms for mid- to late-stage translational research.
1. Classical Neurotoxin Models: MPTP vs. 6-OHDA
Neurotoxin-induced models remain widely used because they are accessible, inexpensive to run, and produce substantial loss of dopaminergic neurons. What separates them is where the damage lands and how long it lasts.
MPTP Model (Mouse / Monkey)
Mechanism: MPTP is metabolized to MPP⁺, which selectively inhibits mitochondrial complex I, causing dopaminergic neuronal death. The conversion happens after the compound crosses into the brain, so the lesion forms along the nigrostriatal pathway.
Applications:
- Motor deficits and oxidative stress research
- Pharmacological screening
- PK/PD correlation studies
Model Variants:
- Acute: Single high-dose injection with rapid symptoms but partial spontaneous recovery
- Chronic: Repeated low-dose administration, mimicking progressive degeneration
Limitations:
- Limited Lewy body formation
- Mouse model shows strong recovery capacity
That recovery capacity narrows the window in which a candidate can show benefit, and a negative result may reflect the schedule rather than the compound.
6-OHDA Model (Rat)
Mechanism: Unilateral injection of 6-OHDA induces selective dopaminergic neuron degeneration. Motor asymmetry is quantified using apomorphine-induced rotations.
Applications:
- Stem cell transplantation efficacy
- Deep brain stimulation (DBS) studies
Advantages:
- Clear, quantifiable rotation behavior
- Straightforward surgical approach
Limitations:
- Lack of α-synuclein aggregation
- Does not capture chronic progressive pathology
Although widely used, these toxin models provide only partial recapitulation of human PD and are insufficient for evaluating long-term cell integration and safety, areas where NHPs are essential. A toxin removes neurons. It does not reproduce protein aggregation, the spread of pathology over time, or the inflammatory environment a disease-modifying strategy has to act on.
2. Genetic Models: Tools for Mechanism-Oriented Research
When investigating PD etiology or specific pathogenic pathways, genetic models enable controlled manipulation.
α-Synuclein (SNCA) Overexpression Models
Features: Overexpression of human α-synuclein (e.g., A53T mutant) leads to protein aggregation and Lewy body-like pathology.
Applications:
- Familial PD mechanisms
- α-synuclein targeting therapeutics
- Cell therapy rescue studies
Parkin / DJ-1 Knockout Models
Features: Models display mitochondrial autophagy defects and relatively mild dopaminergic loss but exhibit non-motor symptoms such as cognitive impairment.
Applications:
- Oxidative stress and mitochondrial dysfunction
- Early-stage disease mechanism research
Although genetic models clarify molecular mechanisms, their clinical translatability remains limited. A single-gene defect accounts for a small share of clinical cases, and rodent phenotypes tend to be milder than the human disease. For cell therapy and advanced biologics, NHP models provide stronger predictive value.
3. Nonhuman Primates in PD Research: Where The Model Translates
NHPs, particularly cynomolgus and rhesus monkeys, are the closest species to humans in terms of basal ganglia anatomy, neural circuitry, and behavioral phenotypes. That proximity carries most of the translational weight for cell therapies, viral gene therapies, and biologics targeting the CNS, because the endpoints a sponsor needs can be measured in a human-like brain.
Modeling Approach
The guideline recommends chronic MPTP induction to mimic progressive dopaminergic degeneration and long-term functional decline.
Evaluation Framework
Comprehensive evaluation is essential for clinical translatability:
- Kurlan Rating Scale: Quantifies tremor, bradykinesia, posture, and gait
- Fine Motor Tasks: e.g., box-and-board or food retrieval tests assessing upper-limb dexterity
- Cognitive Function: Delayed-response tasks reflecting executive function impairment
- Imaging Support (optional): PET/SPECT/MRI for dopamine transporter visualization, cell survival tracking, and structural analysis
At Prisys Biotech, these behavioral and imaging readouts are integrated with our AI-based NHP Behavior Analysis System, enabling objective and high-resolution motor and cognitive quantification. The Clinical Imaging platform covers the modalities listed above.
4. Behavioral Assessment: Multi-Dimensional Functional Evaluation
The guideline emphasizes multi-modal behavioral testing rather than reliance on a single score:
|
Test
|
Dimension
|
Key Indicators
|
|
Pole Test
|
Agility, coordination
|
Descending latency
|
|
Rotarod
|
Motor coordination
|
Time to fall
|
|
Gait Analysis
|
Gait pattern
|
Step length/width
|
|
Apomorphine-Induced Rotation
|
Lesion severity
|
>7 turns/min indicates significant asymmetry
|
These quantitative endpoints are essential for evaluating functional recovery following stem cell transplantation, gene therapy, or neuromodulatory interventions. Disagreement between the tests is informative: an animal that improves on the rotarod but not the pole test has coordination without agility.
5. Model Selection Decision Tree: Matching Models to Research Objectives
The 2025 guideline provides a structured decision-making framework.
Drug Discovery (Screening & Optimization)
Preferred: MPTP mouse or 6-OHDA rat
Goal: Rapid efficacy screening and PK/PD correlation
Exposure data for that correlation come from the Pharmacokinetics (PK) package, where a plasma profile is paired with a motor score.
Cell Therapy / Regenerative Medicine
Preferred: Chronic MPTP monkey model
Rationale: Long-term survival, integration, and safety assessment
Mechanism Studies
Genetic mechanisms: SNCA overexpression
Mitochondrial dysfunction: Rotenone model
Complex interactions: Combined genetic + neurotoxin approaches (e.g., α-synuclein overexpression + MPTP)
For studies intended for IND-enabling validation or late-stage translational research, NHPs offer stronger predictive value, because the readouts regulators ask about, including long-term graft survival and behavioral recovery, can be measured directly.
6. Future Directions: Beyond Traditional PD Models
While animal models remain indispensable, emerging technologies are reshaping PD research:
iPSC-Derived Dopaminergic Neurons
Allow personalized drug testing using patient-specific cells.
Brain Organoid-Animal Chimeric Models
Enable in vivo evaluation of human-derived neuronal circuits and graft-host integration.
Integrated Approaches
Future PD modeling will likely combine:
- Classical NHP models
- Human-origin organoids
- Advanced imaging
- AI-driven quantitative behavioral analysis
to construct more accurate and clinically predictive disease systems. An organoid shows what human neurons do in isolation, an NHP shows what a whole brain does.
About Prisys Biotech
Prisys Biotech specializes in NHP preclinical pharmacology, offering validated MPTP-induced PD monkey models and AAV-α-Synuclein Overexpression NHP Model, real-time imaging platforms, and AI-based behavioral quantification systems. We support global biotech and pharmaceutical partners in cell therapy evaluation, biologics development, and CNS translational research.
